Herpes simplex virus type 1-thymidine kinase (HSV1-TK) in combination with ganciclovir is an efficient and widely used strategy in brain tumour gene therapy. Recently, we have shown effective inhibition of glioma growth in a syngeneic rat model using recombinant adenoviruses expressing the full-length HSV1-TK and an N-terminus truncated variant, HSV1-⌬TK in the presence of ganciclovir. We also showed active chronic brain inflammation in the long-term survivors (3 months) treated with HSV1-TK plus GCV. Furthermore, our results indicated loss of myelinated fibres, oedema and indices of ongoing axonal degeneration. In this study, we assessed the cytotoxicity of both HSV1-TK variants in the presence or absence of ganciclovir, in primary cultures of neurones and glia, and in the rat brain in vivo. Our results Keywords: thymidine kinase; brain tumours; flow cytometry; neurological; cytotoxicity Retroviral, adenoviral, and herpes simplex virus type 1-mediated transfer of the HSV1-TK gene to mammalian brain tumour cells in combination with the peripheral administration of the nucleoside analogue ganciclovir (GCV) has been shown to be efficient as an antitumoral strategy in several preclinical studies.
Retroviral, adenoviral, and herpes simplex virus type 1-mediated transfer of the HSV1-TK gene to mammalian brain tumour cells in combination with the peripheral administration of the nucleoside analogue ganciclovir (GCV) has been shown to be efficient as an antitumoral strategy in several preclinical studies. [1] [2] [3] [4] [5] [6] [7] [8] Using this approach, several clinical trials for the treatment of different kinds of tumours have been initiated, 9 including clinical trials for brain tumours using retroviruses and adenoviruses encoding HSV1-TK in combination with GCV. 10 When recombinant adenoviruses (RAds) encoding HSV1-TK are administered into the brain, they will also infect (and might be cytotoxic for) peritumoral normal neurones and other non-tumoral cells in the CNS (eg glia, endothelium, microglia, meningeal cells). High-dose adenovirus-mediated HSV1-TK gene transfer to baboon (1.5 × 10 9 total plaque forming units (p.f.u.)) and rhesus monkey brain (1.5 × 10 11 total p.f.u.) led to gliosis, indicate that, at viral doses where tumour cells are sensitive to the enzyme/prodrug system, (1) there is no major cytotoxicity for either neurones or glial cells grown in primary cultures, (2) on its own the full-length HSV1-TK is more cytotoxic than its truncated version HSV1-⌬TK for a population of non-neuronal and non-glial cells within neocortical primary cultures, and (3) in vivo, when delivered into the striatum, RAds encoding HSV1-TK are more cytotoxic than RAds encoding HSV1-⌬TK, after administration of ganciclovir. The effectiveness of HSV1-⌬TK in preventing brain tumour growth in vivo, combined with its reduced cytotoxicity, both in vivo and in primary cultures of CNS cells, could represent an advantage for treatment of brain tumours using gene therapy. Gene Therapy (2000) 7, 679-685.
necrosis, meningitis and even death upon GCV administration. 11, 12 In vitro, Maron and co-workers 13 recently described that RAd-TK plus GCV is cytotoxic for astrocytes grown in primary culture. Work from our laboratory has recently shown that both HSV1-TK and an Nterminus truncated version HSV1-⌬TK, encoded by recombinant adenoviruses are equally effective in inhibiting the growth of CNS-1 glioma cells in Lewis rats. 1 We also showed active brain inflammation, demyelination and indices of ongoing axonal degeneration, 3 months after successful inhibition of glioma growth after treatment with the recombinant adenovirus expressing the full-length HSV1-TK. 1 We therefore considered it of critical importance to study the cytotoxicity of HSV1-TK and HSV1-⌬TK within infected cells from the rat central nervous system in vitro, and in the rat brain in vivo. Our results show that neither neurones nor glial cells in primary cultures were killed by HSV1-⌬TK or HSV1-TK alone, or by GCV on its own. However, HSV1-TK was more toxic, both on its own and in the presence of GCV, to non-neuronal/non-glial cells present in primary CNS cell cultures, when compared with HSV1-⌬TK. Similarly, the nonspecific toxicity, as well as the activation of astroglia and infiltration of inflammatory cells was much higher in animals injected with RAd expressing HSV1-TK when compared with HSV1-⌬TK. Thus, the in vitro and in vivo results presented in this paper shed light on the inherent direct cytotoxicity of HSV-TK towards neurones, glial and other brain cells in the absence of inflammatory and immune cells (in vitro), and in their presence (in vivo).
RAd127 (HSV1-⌬TK) and RAd128 (HSV1-TK) were generated by homologous recombination between the left-hand side of the adenoviral genome in pJM17 and the plasmid pAL119, containing the sMIEhCMV promoter 14 upstream of HSV1-TK or HSV1-⌬TK, followed by the SV40 polyadenylation sequence as described previously. 1 Cell suspensions harvested from rat primary neocortical neuronal cultures infected with RAd127 or RAd128, were double immunostained to detect simultaneously the expression of cell type-specific neuronal (MAP-2) or glial (GFAP) markers, in combination with either transgene protein levels or apoptosis, using flow cytometry. The percentage of MAP-2-positive cells was 98% at 2 days after plating, and 69% at 6 days after plating. The percentage of GFAP expressing astrocytes increased from 1% to 10%, indicating ongoing cell division of non-neuronal cells (results not shown). Due to their low concentration in primary neuronal cultures, the population of astrocytes was electronically enriched to allow their analysis by flow cytometry. Enrichment was done by taking advantage of the astrocytes' higher cytoplasmic granularity (side scatter signal), and bigger size (forward scatter signal), compared with neurones. However, cells were classed as neurones by their MAP-2 immunoreactivity, or as glial cells through their GFAP immunoreactivity. Cells negative for both MAP-2 and GFAP (likely to represent fibroblasts, endothelial cells and/or microglia) were also analysed. Our cultures did not contain cells immunoreactive for ␤-galactocerebrosidase (a marker for oligodendrocytes). Both neurones and astrocytes expressed HSV1-TK and HSV1-⌬TK driven by the sMIEhCMV promoter (results not shown).
To study the conditional toxicity of adenovirally encoded HSV1-TK or HSV1-⌬TK plus GCV for astrocytes and neurones, we analysed the percentage of apoptotic neurones and astrocytes by flow cytometry. 15 Neuronal cultures were infected 24 h after plating with RAds with 5 × 10 7 IU added per well (approximate MOI 30) for 48 h, followed by GCV (10 m) treatment for 3 days ( Figure  1 ). RAd127 and RAd128 were not cytotoxic to either neurones or astrocytes in the presence or absence of GCV (P у 0.05; RAd127 + GCV, and RAd128 + GCV versus any other treatment group) ( Figure 1a ). However, we detected significant levels of apoptosis when we analysed MAP-2 and GFAP double negative cells. In the presence of GCV, RAd128 caused 43% apoptosis (P Ͻ 0.001; RAd128 + GCV versus all other treatment groups); in the absence of GCV, RAd128 caused 38% apoptosis in this cell population (P Ͻ 0.001; RAd128 versus all other treatment groups). The increased apoptosis after adding GCV was small but statistically significant (P Ͻ 0.001; RAd128 versus RAd128 + GCV). RAd127, however, was less toxic for non-neurones/non-glial cells showing 7% apoptosis in the presence of GCV (P Ͻ 0.001; RAd127 + GCV versus RAd127, and also versus all other treatment groups), and only basal levels of apoptosis (1%) were detected in the absence of GCV (not significant; RAd127 versus all other treatment groups). However, due to the low percentage of astrocytes (Ͻ10%) present in primary neuronal cultures, we also studied the toxicity of our system in primary glial cultures, in which 40-50% of the population is GFAP immunoreactive. Thus, to determine if the toxicity of HSV1-TK and HSV1-⌬TK plus GCV is dependent on whether the cells are replicating or not we plated the cells at two den- 
Figure 1 (a) Rat neurones in primary cultures: cytotoxicity of RAds expressing HSV1-⌬TK and HSV1-TK. Cultures were characterised using specific antibodies by flow cytometry: MAP-2-positive cells (neurones), GFAP-positive cells (astrocytes), and MAP-2/GFAP-negative cells

f). No HSV1-TK immunoreactivity was found in animals treated with RAd␤-gal (IIi-l). More intense HSV1-TK immunoreactivity was found at the higher dose of viral vector and in animals injected with RAd128 (IIa-h).
sities: high, confluent (non-dividing conditions) and low, non-confluent (dividing conditions).
Analysis of GFAP immunoreactive cells indicated that, in low-density culture (Figure 1b , left panels), neither RAd127 nor RAd128 (MOI 30) per se were toxic, either in the absence or presence of GCV (P у0.05; RAd127 + GCV versus all other treatments, or RAd128 + GCV versus all Gene Therapy other treatments). In high-density cultures (Figure 1b , right panels), neither virus was cytotoxic in the absence of GCV (10 m) (P у0.05; RAd127 and RAd128 versus uninfected, and uninfected + GCV). In the presence of GCV, however, RAd128 killed 8% of the astrocytes (P Ͻ 0.001; RAd128 + GCV versus RAd128).
Analysis of GFAP-negative cells in low-density culture
Figure 3 Infiltration of machrophages/microglia (ED1 immunoreactive I) and astrocytes (GFAP immunoreactive II) cells in vivo following administration of RAd127 and RAd128 into the brain. Up-regulation of ED1 and GFAP immunoreactivity was present in all animals. ED1 and GFAP immunoreactivity in animals treated with RAd␤-gal did not increase following GCV treatment but did increase with a higher viral dose (Ii-l; IIi-l). Animals injected with RAd128 or RAd127 showed similar increases in ED1 and GFAP immunoreactivity with higher viral doses (Ic, d, g, h; IIc, d, g, h). Further increased ED1 and GFAP immunoreactivity was observed in animals treated with ganciclovir (Ib, d, f, h; IIb, d, f, h).
( Figure 1b , left panels) indicated that HSV1-⌬TK was non-cytotoxic per se (P у0.05; RAd127 versus uninfected, and uninfected + GCV). In the presence of GCV, RAd 127 was cytotoxic (P Ͻ 0.001; RAd127 + GCV versus RAd127). HSV1-TK however, was cytotoxic in the absence of GCV (25% apoptosis) (P Ͻ 0.001; RAd128 versus uninfected, uninfected + GCV, RAd127, RAd127 + GCV). In the presence of GCV, the toxicity of RAd128 was significantly increased (40% apoptosis) (P Ͻ 0.001; RAd128 + GCV versus RAd128). Analysis of GFAP-negative cells in high-density culture (Figure 1b , right panels) indicated that HSV1-⌬TK was non-cytotoxic per se (P у0.05; RAd127 versus uninfected, and uninfected + GCV). In the presence of GCV, RAd 127 was cytotoxic (P Ͻ 0.0001; RAd127 + GCV versus RAd127). HSV1-TK however, was cytotoxic in the absence of GCV (55% of apoptosis) (P Ͻ 0.001; RAd128 versus uninfected, uninfected + GCV, RAd127, RAd127 + GCV). In the presence of GCV, the toxicity of RAd128 was significantly increased (65% apoptosis) (P Ͻ0.001; RAd128 + GCV versus RAd128).
These results show that in vitro, high levels of HSV1-TK and HSV1-⌬TK proteins expressed in neurones and glial cells, are not cytotoxic even after the addition of ganciclovir. Nevertheless, a population of non-neuronal/ Gene Therapy non-glial cells was very sensitive to the transduction with adenoviruses encoding HSV1-TK, but much less sensitive to the toxicity of HSV1-⌬TK. This suggests that much of the neuronal and glial toxicity detected in vivo could depend on the inflammatory and immune reactions to either the viral vector, and/or transgenes.
We injected two doses of adenoviral vectors, 8 × 10 6 IU and 8 × 10 7 IU, which have previously been used by us and others in experimental trials of glioma gene therapy and gene transfer into the brain. Animals were injected with either dose, of RAd127, RAd128, or RAd␤-gal, used as a control. Animals were then treated either with ganciclovir or saline twice daily for 7 days, and killed immediately after the 7th day of treatment to determine whether the short-term inflammatory reaction was dependent on the vectors themselves, the transgene, or the combination of vector expressing the transgene and ganciclovir. Brains were cut serially, and adjacent vibratome sections were stained for Nissl or immunoreacted to detect the presence of transgene (ie using antibodies against HSV1-TK) (Figure 2) , activated macrophages/microglial cells (ie using antibodies recognizing ED1), astrocytes (ie using antibodies against with GFAP) (Figure 3 ), CD4
+ and CD8 + lymphocytes (Figure 4 ). No brain lesion (Figure 2 Ii-l) or HSV1-TK immunoreactivity (Figure 2 II i-l) was detected in the brains of animals injected with RAd␤-gal, at either dose, either in the absence or presence of ganciclovir. In these brains we detected only an increase in the infiltration of ED1 immunoreactive macrophages/microglial cells that did not increase following the ganciclovir treatment ( Figure 3 Iil), and an increase in GFAP immunoreactivity ( Figure 3 IIi-l). Infiltration of macrophages/microglia (ED1) and astrocytes (GFAP) was higher with the higher viral vector dose (Figure 3 Ik-l and 3 IIk-l). There was a small but significant infiltration of CD4 + and CD8 + cells at the 8 × + and CD8 + lymphocytes, was correspondingly higher in animals injected with RAd128 and treated with ganciclovir. The lesion induced in vivo was more important in animals injected with RAd128 and treated with ganciclovir (Figures 2-4) . Infiltration of ED1 (Figure 3 I) 
cells, CD4
+ (Figure 4 I ) and CD8 + (Figure 4 II) lymphocytes, was stronger in animals injected with RAdTK, compared with animals injected with either RAd⌬TK or RAd␤-gal, even in the absence of ganciclovir treatment, indicating that rapid inflammatory infiltration in the brain is not only viral vector and vector dose-dependent, but also depends on the transgene expressed by the viral vector. Our in vitro results suggest that in vivo toxicity is not a consequence of direct toxicity to neuronal or glial cells. Therefore, the in vivo inflammation could be due to the toxicity towards non-neuronal and non-glial cells, a fact overlooked by previous studies. In addition to the lower direct toxicity elicited by HSV1-⌬TK for brain cell cultures, this gene could also be useful in avoiding or reducing, for example, the liver-associated toxicity showed by HSV1-TK/GCV treatment. 16 In summary, our in vivo experiments demonstrated that RAd128 expressing HSV1-TK was more inflammatory than RAd127, expressing a truncated HSV1-⌬TK, in the absence and in the presence of ganciclovir. Our data suggest that the in vivo toxicity could be due to inflammatory or immune responses to the vectors, combined with the toxicity for non-neuronal, non-glial cells within normal peri-tumoral tissue, eg endothelial cells. The fact that HSV1-⌬TK can efficiently inhibit tumour growth in vivo, 1 and displays significantly reduced toxicity for normal brain cells in vitro and in vivo represents an advantage for glioma gene therapy. 17 Thus, HSV1-⌬TK encoded within a replication-deficient adenovirus vector could be exploited for the treatment of brain tumours to achieve clinically relevant levels of tumour cell killing, coupled with a reduced cytotoxicity for the surrounding nontumoral brain tissue.
